Your session is about to expire
← Back to Search
Psilocybin for Depression
Study Summary
This trial will study the effects of psilocybin on people with major depressive disorder who haven't responded to other treatments.
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2021 Phase 2 trial • 95 Patients • NCT02061293Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have a high score on a reading test called the Wechsler Test.You have had problems with alcohol or drugs within the past year, as determined by a standardized assessment called DSM-5.You have depression caused by other serious medical conditions.You are currently taking benzodiazepines every day.You have a score higher than 40 on a reading test for adults called the Wechsler Test.You have uncontrolled diabetes that requires insulin.You are right-handed according to a test called the Edinburg Handedness Inventory.You recently had a stroke or heart attack within the past year. You have high blood pressure or abnormal heart rhythms. You are currently taking medication to thin your blood. You have a condition called aneurysmal disease.Your score on the McLean Screening Instrument for Borderline Personality Disorder (MSI-BPD) needs to be less than 7 during the screening process.You have received electroconvulsive therapy or ketamine for your current condition in the past.You have a high risk of causing harm to others based on a clinical interview.You have been diagnosed with moderate or severe depression by a doctor using a special interview called the Mini International Neuropsychiatric Interview (MINI).You have a history of certain mental health conditions like schizophrenia, bipolar disorder, or personality disorders that may affect your ability to participate in the study.You have had thoughts of harming yourself or have engaged in self-harming behaviors within the past year, or a healthcare professional has determined that you are at significant risk of suicide.You have personal circumstances or behaviors that may make it difficult to build a connection or have a safe experience with psilocybin. Additionally, you have used psilocybin or other similar drugs within the past year.Your score on a test called the McLean Screening Instrument for Borderline Personality Disorder (MSI-BPD) needs to be less than 7 during the screening.You have a condition that causes seizures.You have been diagnosed with moderate to severe depression by a doctor using a structured interview called the MINI.You must be able to sign the informed consent form (ICF).You are between the ages of 18 and 55 years.
- Group 1: Psilocybin
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What are the targeted outcomes of this clinical research?
"The primary purpose of this research is to evaluate the alteration in MGH-RQ scores over baseline, administration day and 3/12 weeks post psilocybin. Secondary objectives include an examination of changes in IAT (implicit attitudes task), MADRS(Montgomery-Asberg Depression Rating Scale) and PSWQ (Penn State Worry Questionnaire)."
Who is the target demographic for this research investigation?
"This clinical trial seeks to enroll 20 individuals, aged 18-55 and diagnosed with unipolar depression. Essential criteria include the ability to sign an Informed Consent Form (ICF), a score of at least moderate on the Mini International Neuropsychiatric Interview Version 7.02 (MINI) and Hamilton Depression Rating Scale - 17 item (HAM-D-17). Other eligibility requirements are failure to respond adequately to two or more pharmacological treatments for their current episode as determined by Massachusetts General Hospital Antidepressant Treatment History Response Questionnaire (MGH-ATRQ); a McLean Screening Instrument for Borderline personality disorder (MSI"
Has the FDA sanctioned Psilocybin for medical use?
"Psilocybin's safety has been backed up by evidence, so it rated a 2. This Phase 2 trial lacks any data on efficacy though."
What is the current number of participants enrolled in this investigation?
"Affirmative. According to information provided on clinicaltrials.gov, this medical experiment is actively recruiting participants; it was initially posted on September 15th 2022 and recently updated the day after. 20 subjects are being enrolled from a single location."
Is this medical study open to geriatric patients?
"Eligibility for this trial requires participants to be within the age bracket of 18-55. Conversely, there are 105 studies in which those younger than 18 can take part and 591 trials that accommodate seniors over 65 years old."
Are there still vacancies for the clinical trial available to participants?
"According to details hosted on clinicaltrials.gov, this trial is actively recruiting patients and has been since September 15th 2022. The study was recently updated on the 16th of that same month."
Who else is applying?
What state do they live in?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Why did patients apply to this trial?
What questions have other patients asked about this trial?
How responsive is this trial?
Average response time
- < 2 Days
Typically responds via
Most responsive sites:
- Athinoula A. Martinos Center for Biomedical Imaging: < 24 hours
Share this study with friends
Copy Link
Messenger